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Background and purpose: The recent SARS-CoV-2 pandemic has posed
multiple challenges to the practice of clinical neurology including recog-
nition of emerging neurological complications and management of coex-
istent neurological diseases. In a fast-evolving pandemic, evidence-based
studies are lacking in many areas. This paper presents European Acad-
emy of Neurology (EAN) expert consensus statements to guide neurolo-
gists caring for patients with COVID-19.
Methods: A refined Delphi methodology was applied. In round 1, state-
ments were provided by EAN scientific panels (SPs). In round 2, these state-
ments were circulated to SP members not involved in writing them, asking for
agreement/disagreement. Items with agreement >70% were retained for
round 3, in which SP co-chairs rated importance on a five-point Likert scale.
Results were graded by importance and reported as consensus statements.
Results: In round one, 70 statements were provided by 23 SPs. In round
two, 259/1061 SP member responses were received. Fifty-nine statements
obtained >70% agreement and were retained. In round three, responses
were received from 55 co-chairs of 29 SPs. Whilst general recommenda-
tions related to prevention of COVID-19 transmission had high levels of
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agreement and importance, opinion was more varied concerning state-
ments related to therapy.
Conclusion: This is the first structured consensus statement on good
clinical practice in patients with neurological disease during the COVID-
19 pandemic that provides immediate guidance for neurologists. In this
fast-evolving pandemic, a rapid response using refined Delphi methodol-
ogy is possible, but guidance may be subject to change as further evi-
dence emerges.
Introduction
In December 2019, a new viral disease causing respira-
tory symptoms was described in the Wuhan area in
China [1]. Severe acute respiratory syndrome – coron-
avirus 2 (SARS-CoV-2) was identified causing coron-
avirus disease 2019 (COVID-19). On 11th March, the
World Health Organization declared the COVID-19
outbreak a pandemic, after the disease had spread
across the world to 114 countries at the time [2]. With
the high number of infected people stressing global
healthcare systems, capacity in both primary and hos-
pital care settings were overwhelmed. It quickly
emerged that a substantial proportion of COVID-19
patients presented with neurological symptoms, sug-
gesting either direct neurotropism or secondary effects
of the virus on the central and peripheral nervous sys-
tem [3–5]. Lockdown measures ensued in many coun-
tries across Europe and beyond to contain viral
spread, including social distancing and interruption of
elective healthcare services. These measures changed
lives for the majority of people with specific impact
on those living with chronic neurological diseases.
With little to no evidence-based information on the
new disease available as the pandemic rapidly esca-
lated, the European Academy of Neurology (EAN)
started to publish expert advice to guide clinical prac-
tice for neurologists during the pandemic on their
EANcore COVID-19 website. With this paper, the
first consensus statement on neurological care and
COVID-19 is presented.
Method for reaching consensus
The EAN has expert groups organized into 29 scien-
tific panels (SPs) covering almost all neurological spe-
cialist areas. SPs consist of neurologists and trainees
with special interest in that field and comprise repre-
sentatives of each European national neurological
society (up to 47), and a variable number of individ-
ual members, residents, research fellows and patient
representatives. The SPs are usually led by two elected
co-chairs and a management group, including up to
three elected members of the SP, a representative of
the EAN residents and research fellow section and,
where applicable, a representative of any subspecialty
society holding a memorandum of understanding with
EAN.
Refined Delphi process
A refined Delphi process through three rounds of sur-
veying members of the EAN SPs was conducted to
generate a structured consensus statement.
In the first round, on 31 March 2020, all 29 SPs were
invited to submit expert advice on good clinical practice
in patients with neurological disease during the
COVID-19 pandemic. Twenty-three submissions were
received by 17 April 2020, written by SP co-chairs or up
to five members of the SP management group. All SP
expert statements are available at the following link:
https://www.eanpages.org/category/academic_scientif
ic/scientific_panels_report/. The statements provided
by the 23 SPs were retrospectively regarded as round 1.
For the second round, the items of those expert
advice were entered into a survey questionnaire with a
five-point Likert scale to determine the level of agree-
ment (strongly agree/agree/neutral/disagree/strongly
disagree). This questionnaire was sent to all members
of the SPs who were not involved in writing the origi-
nal statements. The recommendations were displayed
in random order to the participants to avoid sequence
bias. Answers were recorded anonymously but a core
set of demographic data was obtained in the first sec-
tion of the questionnaire (Table S1). Items voted
’strongly agree’ or ’agree’ by ≥70% of members were
selected to proceed to the next round. The other items
were removed from the process at this stage.
In round 3, all remaining items were again entered
into a survey questionnaire with a five-point Likert
scale and submitted only to the co-chairs of each SP,
asking to rate importance of the statement (absolutely
essential/very important/average importance/little
importance/no importance at all). Between 5
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(absolutely essential) and 1 (no importance at all)
points were recorded for each item and an average for
each item was calculated and reported as an impor-
tance score. Demographic data were again collated
using the same questions as in round 2 and anon-
ymized responses were provided.
Results
In the first round, 23 SP reports from 29 SPs (re-
sponse rate 79%) were received. From these state-
ments, single items were extracted and, after removal
of duplicates, 70 statements were listed in a single
document for the questionnaire applied for the second
round.
In the second round, 1061 potential respondents were
approached. 259 (24%) responded within the required
period of 1 week. Overall, responses were received from
35 countries (out of 47 EAN institutional member
countries). The nationalities with the highest number of
respondents were Italy (14%), Germany (8%), Austria
(7%) and Greece (6%). Sixty-six percent of respondents
were male and 34% female. The median age of respon-
dents was 51 years (range 26–75 years). Twelve per cent
of respondents were continuously, 49% occasionally
involved in the care of patients with COVID-19; 39%
reported no involvement at all. Respondents repre-
sented all 29 SPs with the most common subspecialties
being multiple sclerosis (26%), stroke (24%), neuroim-
munology (17%), clinical neurophysiology (16%) and
movement disorders (15%).
Fifty-nine items received agreement from 70% or
more of respondents. Eleven recommendations did
not reach this level of combined agreement and were
excluded from round 3 (Table S2).
The third-round questionnaire was sent to 55 SP co-
chairs, 48 of whom responded within the required time
period of 1 week (87% response rate). 70.8% of respon-
dents were male and 29.2% female.Median age of respon-
dents was 51 years (range 34–73 years). 75% of
respondents reported involvement in the care of COVID-
19 patients and 18.8% continuous involvement. The most
commonly specified subspecialties were multiple sclerosis
(20.8%), movement disorders (20.8%), stroke (18.7%),
amyotrophic lateral sclerosis and frontotemporal demen-
tia (14.6%), clinical neurophysiology (12.5%), epilepsy
(12.5%), neuroimmunology (12.5%), muscle and neuro-
muscular junction disorders (12.5%) and dementia and
cognitive disorders (12.5%).
Consensus statements
The 59 agreed items were divided into general or neu-
rology specific advice. Statements on general measures
mostly echo the general recommendations of hygiene
and social distancing, or general advice on disease
management but not specific to COVID-19
(Table S3).
Neurology and COVID-19 specific recommenda-
tions were divided into the following sections:
• Organization of care (Table 1)
• Management and therapy of neurological symptoms
(Table 2)
• Management and therapy of neurological complica-
tions (Table 3)
• Considerations for patients with chronic neurologi-
cal conditions (Table 4)
General recommendations and recommendations on
organization of care, with only few exceptions,
received the highest levels of agreement (>90%)
(Tables S3 and 1). Agreement on management and
therapy of neurological symptoms and syndromes ran-
ged from 70% to 88% (Table 2). Agreement on man-
agement and therapy of neurological COVID-19
complications ranged from 78% to 94% (Table 3),
whereas agreement on recommendations for patients
with chronic neurological conditions during the
COVID-19 pandemic ranged from 75% to 97%
(Table 4). Agreement around pharmacological treat-
ments for specific immune-mediated diseases was gen-
erally lower compared to more general therapeutic
approaches. The importance score reflected mostly
agreement from round 2.
Discussion
With this consensus statement, the EAN provides neu-
rologists with structured recommendations based on
broad consensus for good clinical practice in the care
of patients with neurological diseases during the
COVID-19 pandemic. Recommendations are wide-
ranging; some statements refer to neurological
involvement in patients suffering from COVID-19,
and the guidance includes advice on changes in service
provision and prevention of infection amongst clini-
cians and other staff. Therefore, they may guide devel-
opment of local standard operating procedures and
help to convince healthcare providers on the impor-
tance of continuing supportive care in patients with
chronic and acute neurological diseases.
To the best of our knowledge, this is the first con-
sensus statement on COVID-19 produced by struc-
tured design, involving experts in several subfields of
neurology. Other neurological societies have presented
a guidance based on expert advice derived from indi-
vidual or committee experience [6,7] but without a
structured method of agreement on items and cover-
ing only specific aspects of neurology care [8–14].
© 2020 The Authors. European Academy of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Some subspecialty societies have issued structured
expert recommendations, which were open for discus-
sion on their respective websites and approved by the
board [15,16]. The EAN consensus recommendation
method incorporates progressive evaluation of agree-
ment and importance of each item in three phases,
involving an escalation of expertise across rounds. It
is proposed that this structured refined Delphi process
results in a broad and robust consensus statement
with a high level of transparency. The breadth of
expertise is illustrated by our second round on agree-
ment, with involvement of 259 participants represent-
ing many different countries, national neurological
societies, neurological subspecialties and patient repre-
sentatives.
It is important to note that some of our statements
refer to experiences during the peak of the first wave
when high numbers of patients were suffering from
COVID-19. Once the first wave has passed, the appli-
cability of self-isolation and other infection control
measures may be re-evaluated, according to the local
prevalence of infection and official regulations.
However, it should be borne in mind that many of
the statements here refer to patients with neurological
disorders that may confer a particular vulnerability to
complications of COVID-19, and so they may remain
relevant for some time. It is unclear at the time of
writing whether the pandemic will evolve into a sec-
ond wave. If so, it may be necessary to readapt our
clinical practice and consensus statements to address
rapidly changing circumstances, considering both
varying national and regional recommendations and
variation in infection and building on progress to
date.
There are limitations of these consensus recommen-
dations. First, the call for statements from SPs was
designated in round 1 retrospectively, and prospective
declaration may stimulate a higher response rate.
However, our response rate of 79% within 18 days is
already high. Secondly, the short response periods of
a week for rounds 2 and 3 may have reduced response
rates. This might be true especially for round 2 which
had a low response rate of 24%. However, it was still
possible to obtain responses from 259 specialists
Table 1 Recommendations on organization of care during the COVID-19 pandemic
Recommendation
Importance
score
Per cent
agreement
During endovascular treatment for acute stroke patients, special conditions to prevent potential
exposure/contamination with SARS-CoV-2 should be applied without delaying treatment
4.66 96%
Adequate supply of medication and ventilatory support equipment for a period of prolonged isolation must be
ensured
4.42 94%
In the case of respiratory decompensation in patients with neuromuscular disorders, e.g. amyotrophic lateral
sclerosis (ALS), on home ventilatory support or with initial respiratory symptoms, the patient or caregiver
should contact the homecare/palliative team/caring ALS centre and inform the physician who regularly cares
for the patient
4.39 96%
Special hygienic conditions (according to contamination prevention guidelines) must be prepared if
electroencephalographic (EEG) and electromyographic (EMG) investigations are necessary
4.34 98%
Whilst performing neurophysiology investigations, technicians should adhere to the rules being followed by the
intensive care unit (ICU) healthcare staff, including droplet and airborne precautions
4.3 95%
Specialist consultations should be provided over the telephone or where available via teleconsultation. This
may help to identify those patients who need a face to face appointment
4.26 94%
Neurologists must be included in the care of COVID-19 patients, even in the early stages and in the ICU to
detect neurological symptoms and disorders
4.16 73%
Taking into account the shortage of personal protective equipment, and the potential risk of infecting both
healthcare staff and patients, departments are encouraged to postpone all elective EEG and EMG
investigations unless urgent and likely to change management significantly. However, these decisions should
be managed according to local policies and guidelines
4.12 84%
Patients with neuromuscular disorders particularly affecting respiratory function (e.g. ALS) should be confined
to their homes to prevent becoming infected since the impact of respiratory infections is expected to be more
serious than in the general population
3.93 92%
If applicable, a principal carer should be identified: one principal carer should coordinate care provided to the
patient. This carer should remain with the patient in self/social isolation
3.88 80%
Walking aids or wheelchairs, as well as other surfaces, should be disinfected with detergents or products
containing alcohol. This should also include the entrance area, where clothes from the outside are gathered
3.86 90%
If applicable, a back-up carer should be identified for each patient, limiting external contacts to avoid the risk
of spreading the infection
3.59 89%
Consider prolonging follow-up magnetic resonance imaging appointments in asymptomatic, long-term
survivors of less malignant brain tumours, e.g. meningiomas and schwannomas
3.5 77%
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across the full range of neurological specialties, sup-
porting broad-based consensus, and the round 3
response rate of 87% remained high. Thirdly, in
rounds 2 and 3, no further additions were allowed.
This was felt necessary in order to archive a consensus
statement in a short period of time. The time pressure
inherent in crisis response dictated various aspects of
methodology, as rapid action was considered the first
priority to support neurologists dealing with the pan-
demic. It is argued that this limitation may be consid-
ered acceptable in these circumstances and given that
the first round was created by more than 50 authors.
Hence, this is a recommendation based on expert
advice. It does not report evidence-based guidance, as
would be expected in EAN guidelines. A further limi-
tation of this study is that statements might be inter-
preted in different ways. For example, the statement
’Common neurological diseases requiring intensive
care unit admission have to be managed as usual,
independent of COVID 19 infection’ was considered
ambiguous upon review, but was intended to indicate
that usual standards of care in critically ill patients
must not be compromised. Finally, the fast-moving
nature of the pandemic means that updates are likely
to be required as new research results emerge. There-
fore, the validity of the single statements within this
consensus recommendation has to be reviewed as time
and knowledge about the disease evolve. One example
may be the recent announcement of the beneficial
effect of dexamethasone in patients with active
COVID-19 [17]. In our recommendations, careful use
of intravenous steroid pulse therapy for treatment of
neurological diseases is referred to. Although dexam-
ethasone may prove beneficial in active COVID-19
disease [17], little knowledge exists at present if high
dose steroids in neurologically affected individuals
may increase risk of infection with SARS-CoV-2.
Another important example is the diagnostic state-
ment ‘Neurologists must be included in the care of
COVID-19 patients, even in the early stages and in
the intensive care unit to detect neurological symp-
toms and disorders’. This was agreed by 73% of
respondents in round 2, and assigned a mean impor-
tance score of 4.12 in round 3, indicating that SP co-
chairs felt this to be very important to absolutely
essential at the time of the questionnaire. Given subse-
quent emerging data on neurological involvement in
acute COVID-19 [5,18–20], it may be that agreement
Table 2 Recommendations on therapy of neurological symptoms/syndromes during the COVID-19 pandemic
Recommendation
Importance
score
Per cent
agreement
Common neurological diseases requiring intensive care unit admission (e.g. traumatic brain injury, ischaemic
stroke, haemorrhagic stroke, status epilepticus, neuro-immunological diseases and many others) have to be
managed as usual, independent of COVID-19 infection status
4.55 86%
Before starting a cell-depleting therapy (e.g. ocrelizumab, rituximab, alemtuzumab, cladribine), the risk of
immune suppression and susceptibility to infections up to several weeks after treatment initiation must be
considered. It may be advisable to delay initiation of cell-depleting therapies until the peak of the pandemic is
over in the region. For occasional patients, the risk of not starting the cell-depleting therapy may outweigh
the risk of severe COVID-19 infection and this has to be discussed with the patient in detail
4.02 83%
Intravenous corticosteroid pulse therapies that are provided in the absence of a clear clinical indication or
justification should be avoided
4 87%
For therapies with immune-depleting properties or primary immune suppressive agents (e.g. ocrelizumab,
rituximab, cladribine, alemtuzumab, mitoxantrone) in the first weeks after initiation, there could be an
increased risk of infections. In older patients and patients with comorbidity (cardiovascular, pulmonary),
treatment initiation should be delayed (if disease activity allows)
3.98 83%
There is currently no evidence to suggest that intravenous immunoglobulin (IVIG) or plasma exchange (Plex)
carry any additional risk in catching COVID-19. Plex and IVIG should be reserved for patients with acute
exacerbation of neurological disease indications
3.82 75%
For patients with ongoing therapies with immune-depleting properties or primary immune suppressive agents
(e.g. ocrelizumab, rituximab, cladribine, alemtuzumab, mitoxantrone), timing of retreatment with immune-
depleting therapies should be revised by the consultant and delay in treatment is recommended if possible or
alternative options considered
3.82 70%
Paracetamol should preferably be used for antipyretic or analgesic treatment if no contraindications 3.55 86%
Conditions such as orthostatic hypotension or postural orthostatic tachycardia syndrome may occur in
patients recovering from COVID-19 infections resulting from viral illnesses due to gastrointestinal fluid loss,
prolonged bed rest and deconditioning of the cardiovascular and viscero-sensory systems
3.55 77%
Ibuprofen for antipyretic or analgesic use might be considered if deemed necessary and in the absence of
alternatives (see European Medicines Agency advice)
3.41 72%
There is currently no evidence to support the assumption that inhibition of complement using the monoclonal
antibody eculizumab increases susceptibility to COVID-19 infection or its outcome
3.33 70%
© 2020 The Authors. European Academy of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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and importance on this topic would be even higher if
repeated now. Similarly, although the European
Medicines Agency had already issued a statement on
use of ibuprofen in COVID-19 as mentioned in our
statement, further publications over recent weeks have
strengthened the evidence base that ibuprofen appears
safe [21]. Knowledge on use of immunomodulatory
treatment is growing and expert advice already differs
from the consensus statements published here [22-24].
However, it has to be stressed that expert statements
differ from consensus or guidelines and represent a
different perspective and level of evidence.
Furthermore, in an emergency situation such as the
current pandemic, evidence is sparse. Hence, expert
recommendations are more feasible in timeframes nec-
essary to address the need of physicians and patients.
Nevertheless, it will remain mandatory to produce
more formalized fully evidence-based structured guid-
ance during the subsequent course of the pandemic.
Online platforms such as the EANcore COVID-19
area of ean.org allow more rapid updates in this con-
text, as further evidence emerges.
It is believed that the main strength of this paper is
the broad-based multi-specialty input approach used
Table 4 Recommendations for patients with chronic neurological conditions during the COVID-19 pandemic
Recommendation
Importance
score
Per cent
agreement
Patients on immunosuppressive medication should practice extra vigilant social distancing, including avoiding
public gatherings/crowds and avoiding crowded public transport
4.47 94%
Patient information should stress the importance of maintaining concordance with and supply of prescribed
medication
4.45 97%
In any case of acute signs of infection, immune therapies must not be initiated or continued; in particular,
immune-depleting agents should be delayed until symptoms have disappeared
4.2 84%
Extra focus should be put on symptoms of infection as persons with dementia may not report these 4.12 88%
Sphingosine-1-phosphate-receptor-modulators (fingolimod, siponimod) in general are associated with increased
risk of respiratory infections, but cessation of therapy is associated with significant risk of disease activity
returning in multiple sclerosis patients (including rebound activity). Patients should be specifically advised to
confine contacts and minimize risks of infection
4.07 86%
Patients receiving plasma exchange or intravenous immunoglobulin as maintenance therapy should continue
these if necessary, but extra precautions may need to be taken because of the need for travel to and from a
healthcare facility
4.02 75%
Huntington’s and Parkinson’s disease patients may be particularly vulnerable to respiratory infections or
pneumonia due to limited respiratory capacity related to reduced mobility of their thoracic cage. Therefore, it
is important to be vigilant in counselling patients to undertake all precautions for reducing exposure risk
3.93 94%
New treatment options for COVID-19 include antiviral, immunomodulatory and immunosuppressive drugs,
which may have drug–drug interactions with antiepileptic drugs (AEDs). Hence, dose adjustments of AEDs
or COVID-19 treatment might be necessary
3.91 84%
Certain infusion therapies (e.g. natalizumab, rituximab, ocrelizumab, alemtuzumab) may require travel to
infusion centres and it is strongly recommended that this decision be made based on regional incidence of
COVID-19 and risk/benefit balance for the individual patient
3.86 92%
Table 3 Recommendations on overall management of neurological COVID-19 complications
Recommendation
Importance
score
Per cent
agreement
Severe neurological complications can occur in COVID-19 patients during hospitalization, such as seizures,
encephalopathy, encephalitis and cerebrovascular events including ischaemic stroke or intracerebral
haemorrhage
4.35 85%
During the stay in critical care, prolonged intensive care unit (ICU) admission may cause development of
multifactorial encephalopathy, critical illness neuropathy and myopathy
4.3 94%
In ICU, survivors must be evaluated and followed for cognitive impairment, psychiatric and/or physical
disability which is commonly referred to as the post ICU-care syndrome
4.16 86%
In order to understand the biology of the disease, neuropathological examination should be requested in
deceased patients with suspected neuro-invasive SARS-CoV-2 infection to assess for lower brainstem and
medullary involvement
4.12 81%
There may be a higher risk of subacute neurological complications, including Guillain–Barre syndrome and
other autoimmune diseases such as necrotizing encephalitis
4.09 78%
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to produce consensus recommendations rapidly in a
crisis situation, whilst maintaining a scientifically rig-
orous methodology. This methodology could be
applied in future to similar situations if necessary,
when a new medical condition is rapidly evolving and
guidance is needed for doctors in any specialty coming
to terms with new circumstances and challenges. This
would include a possible second wave of COVID-19.
In fact, being prepared for such situations is recom-
mended by identifying potential groups for rounds 2
and 3 and by installing the necessary technical provi-
sion to be able to act quickly. Within this infrastruc-
ture, expert opinion can be rapidly and transparently
assessed using the refined Delphi methodology. This
approach enabled the EAN-COVID-19 task force to
produce these pan-European consensus-based state-
ments which seek to guide harmonization of high-
quality healthcare across Europe in the face of current
challenges. It is hoped that this document helps both
leaders and individual clinicians to adapt to the
crisis for the benefit of our patients with neurological
disorders.
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